Stockscreener 앱 받기
2.93
0.68%
-0.02
전일 마감가:
$2.95
열려 있는:
$2.96
하루 거래량:
171.74K
Relative Volume:
0.27
시가총액:
$47.62M
수익:
-
순이익/손실:
$-64.47M
주가수익비율:
-0.4737
EPS:
-6.1852
순현금흐름:
$-52.33M
1주 성능:
-5.79%
1개월 성능:
-6.98%
6개월 성능:
-50.84%
1년 성능:
-83.87%
1일 변동 폭
$2.93
$3.05
1주일 범위
$2.8037
$3.13
52주 변동 폭
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.93 | 47.62M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures - MSN
HC Wainwright Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q3 EPS Forecast for Jasper Therapeutics Reduced by Analyst - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
UBS Group Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price - Defense World
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75 - Defense World
UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $12 to $25 - 富途牛牛
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline - TipRanks
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays, Competitive Pressures - AInvest
Jasper Therapeutics' Promising Clinical Data and Strategic Focus Earn Buy Rating - AInvest
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks By Investing.com - Investing.com India
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks - Investing.com
Jasper Therapeutics Reports Promising Q2 2025 Results - MSN
BTIG reiterates Buy rating on Jasper Therapeutics stock with $20 price target - Investing.com Canada
JMP reiterates Market Outperform rating on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper Reports Wider Loss in Fiscal Q2 - AOL.com
Jasper Therapeutics shares fall 4.65% after-hours following Q2 2025 earnings report. - AInvest
Jasper Reports Wider Loss in Fiscal Q2 - The Motley Fool
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33) - TipRanks
Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest
Jasper Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jasper Therapeutics shares rise 3.51% intraday after Metagenomi reported positive business updates and financial results. - AInvest
Jasper Therapeutics under investigation for alleged securities fraud. - AInvest
Jasper Therapeutics shares rise 5.70% intraday after Metagenomi appoints Laurence Reid, PhD to its Board of Directors. - AInvest
Jasper Therapeutics Inc (JSPR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
How does the Q2 2025 earnings report affect JSPR's stock price? - AInvest
Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at EF Hutton Acquisition Co. I - 富途牛牛
Jasper Therapeutics WRT JSPRW Q2 2025 Earnings Preview Downside Expected Amid Technical Integration Hurdles - AInvest
Jasper Therapeutics JSPR 2025Q2 Earnings Preview Downside Ahead on Technical Challenges and Report Compilation Errors - AInvest
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Jasper Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView
Jasper Therapeutics shares fall 3.02% intraday after Pomerantz Law Firm investigates claims of securities fraud. - AInvest
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News
What are the latest earnings results for Jasper Therapeutics Inc.Smart Portfolio Planner With Proven Results - Jammu Links News
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - Jammu Links News
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - Jammu Links News
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - Jammu Links News
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - Jammu Links News
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - Jammu Links News
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - Jammu Links News
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Jasper Therapeutics Inc 주식 (JSPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
0.94%
1.72%
자본화:
|
볼륨(24시간):